15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 13 firms covering Moderna Inc, 1 rate it Buy or better, 9 sit at Hold, and 3 rate it Sell or worse, a hold consensus. The target range is very wide, $18.00 to $77.00 (about 4.3x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $42.50 sits 24% below the current $55.81. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.17 next quarter toward $-4.75 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 ratings
Hold
Strong Buy00%
Buy18%
Hold969%
Sell323%
Strong Sell00%
Based on 13 analysts giving stock ratings to Moderna Inc.
As of Jul, 1 of 13 firms rate MRNA a Buy (9 Hold, 3 Sell), the standing distribution of every covering firm's most recent active call.
MRNA EPS & revenue forecast
EPS · NEXT QUARTER
$-1.17
Range $-1.78 – $-0.46 · 13 analysts · +129% YoY
Next period, 13 analysts expect Moderna Inc to earn $-1.17 a share (range $-1.78 – $-0.46), versus $-0.51 a year earlier. Full-year consensus is $-8.66, growing to $-4.75 the year after.
REVENUE · NEXT QUARTER
$905.9M
Range $730.0M – $1.1B · 13 analysts · -11% YoY
Revenue is expected to reach $905.9M (range $730.0M – $1.1B), -10.8% year-over-year. Full-year consensus is $2.1B, rising to $2.6B next year.
Top analysts covering Moderna Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MRNA.
#1
Jessica Fye
JP Morgan · Rank #64
Sell
No targeton MRNA
Overall win rate
52%
+ Follow
#2
Joseph Stringer
Needham · Rank #168
Hold
No targeton MRNA
Overall win rate
36%
+ Follow
#3
Matthew Harrison
Morgan Stanley · Rank #243
Hold
$39.00-30.1% to target
Overall win rate
44%
+ Follow
#4
Edward Tenthoff
Piper Sandler · Rank #277
Buy
$77.00+38.0% to target
Overall win rate
29%
+ Follow
#5
Salveen Richter
Goldman Sachs
Hold
$67.00+20.1% to target
Coverage
—
+ Follow
MRNA stock forecast FAQ
What is MRNA's average 12-month price target?+
The 12 analysts with a live target average $42.50 for Moderna Inc over the next 12 months, ranging from a $77.00 high to a $18.00 low.
Is MRNA stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 13 analyst ratings, 1 are Buy or Strong Buy, 9 are Hold, and 3 are Sell or Strong Sell.
What are the highest and lowest price targets for MRNA?+
The Street-high target is $77.00 (Piper Sandler), and the Street-low is $18.00 (Leerink Partners). The average of all 12 active targets is $42.50.
How many Wall Street analysts cover MRNA?+
13 analysts have an active rating on Moderna Inc, and 12 firms carry a live 12-month price target.
Who is the most accurate analyst covering MRNA?+
Among analysts who currently cover MRNA, Jessica Fye of JP Morgan has the strongest overall Quantellect track record (Rank #64). Their current call is Sell.
What is Moderna Inc's projected EPS for next quarter?+
The consensus estimate is $-1.17 per share (range $-1.78 – $-0.46) across 13 analysts. Full-year EPS is projected at $-8.66, rising to $-4.75 the following year.
How much revenue is Moderna Inc expected to report next quarter?+
Consensus revenue is $905.9M (range $730.0M – $1.1B). Full-year revenue is projected at $2.1B, growing to $2.6B next year.
Have analysts been upgrading or downgrading MRNA lately?+
As of Jul, 1 of 13 firms rate MRNA a Buy (9 Hold, 3 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MRNA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
